{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T11:54:37Z","timestamp":1790250877424,"version":"4.1.0"},"reference-count":23,"publisher":"American Society for Microbiology","issue":"9","license":[{"start":{"date-parts":[[2018,9,1]],"date-time":"2018-09-01T00:00:00Z","timestamp":1535760000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"funder":[{"DOI":"10.13039\/100012399","name":"HHS | Biomedical Advanced Research and Development Authority","doi-asserted-by":"publisher","award":["HHS0100201600038C"],"award-info":[{"award-number":["HHS0100201600038C"]}],"id":[{"id":"10.13039\/100012399","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004337","name":"Roche","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004337","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["Antimicrob Agents Chemother"],"published-print":{"date-parts":[[2018,9]]},"abstract":"<jats:p>Urinary tract infections (UTIs) are a tremendous burden on the health care system due to the vast number of infections resulting in antibiotic therapy and\/or hospitalization. Additionally, these infections are frequently caused by multidrug-resistant (MDR) organisms, limiting the availability of effective antimicrobials.<\/jats:p>","DOI":"10.1128\/aac.02596-17","type":"journal-article","created":{"date-parts":[[2018,7,12]],"date-time":"2018-07-12T06:05:57Z","timestamp":1531375557000},"update-policy":"https:\/\/doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":57,"title":["<i>In Vivo<\/i>\n                    Efficacy of Meropenem with a Novel Non-\u03b2-Lactam\u2013\u03b2-Lactamase Inhibitor, Nacubactam, against Gram-Negative Organisms Exhibiting Various Resistance Mechanisms in a Murine Complicated Urinary Tract Infection Model"],"prefix":"10.1128","volume":"62","author":[{"given":"Marguerite L.","family":"Monogue","sequence":"first","affiliation":[{"name":"Center for Anti-Infective Research and Development, Hartford Hospital, Hartford, Connecticut, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Giovagnoli","sequence":"additional","affiliation":[{"name":"Center for Anti-Infective Research and Development, Hartford Hospital, Hartford, Connecticut, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caterina","family":"Bissantz","sequence":"additional","affiliation":[{"name":"Division of Pharma Research and Early Development, Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd., Basel, Switzerland"},{"name":"Division of Pharmaceutical Science, Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd., Basel, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia","family":"Zampaloni","sequence":"additional","affiliation":[{"name":"Division of Pharma Research and Early Development, Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd., Basel, Switzerland"},{"name":"Division of Immunology, Inflammation and Infectious Diseases, Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd., Basel, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David P.","family":"Nicolau","sequence":"additional","affiliation":[{"name":"Center for Anti-Infective Research and Development, Hartford Hospital, Hartford, Connecticut, USA"},{"name":"Division of Infectious Diseases, Hartford Hospital, Hartford, Connecticut, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"235","reference":[{"key":"e_1_3_3_2_2","doi-asserted-by":"publisher","DOI":"10.1080\/14737167.2017.1358618"},{"key":"e_1_3_3_3_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.idc.2013.09.003"},{"key":"e_1_3_3_4_2","doi-asserted-by":"publisher","DOI":"10.1038\/nrmicro3432"},{"key":"e_1_3_3_5_2","doi-asserted-by":"publisher","DOI":"10.1007\/s13205-017-0879-2"},{"key":"e_1_3_3_6_2","doi-asserted-by":"publisher","DOI":"10.2174\/1874285801711010023"},{"key":"e_1_3_3_7_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.euf.2016.09.006"},{"key":"e_1_3_3_8_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.idc.2016.02.007"},{"key":"e_1_3_3_9_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkv166"},{"key":"e_1_3_3_10_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02184-15"},{"key":"e_1_3_3_11_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.drup.2017.11.002"},{"key":"e_1_3_3_12_2","doi-asserted-by":"publisher","DOI":"10.1177\/0091270006291035"},{"key":"e_1_3_3_13_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02662-14"},{"key":"e_1_3_3_14_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0924-8579(07)70635-0"},{"key":"e_1_3_3_15_2","unstructured":"U.S. Food and Drug Administration. 2014. Microbiology review. Drug approval package: Avycaz. http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2015\/206494Orig1s000MicroR.pdf. Updated 12 March 2015. Accessed 26 January 2016."},{"key":"e_1_3_3_16_2","unstructured":"U.S. Food and Drug Administration. 2017. Microbiology review. Drug approval package: Vabomere. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2017\/209776lbl.pdf. Accessed 23 October 2017."},{"key":"e_1_3_3_17_2","unstructured":"U.S. Food and Drug Administration. 2014. Microbiology review. Drug approval package: Zerbaxa. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2014\/206829lbl.pdf. Accessed 23 October 2017."},{"key":"e_1_3_3_18_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01329-17"},{"key":"e_1_3_3_19_2","doi-asserted-by":"publisher","DOI":"10.4103\/0974-2727.86842"},{"key":"e_1_3_3_20_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2012.05.002"},{"key":"e_1_3_3_21_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.transproceed.2016.01.060"},{"key":"e_1_3_3_22_2","doi-asserted-by":"publisher","DOI":"10.1007\/s10096-014-2124-9"},{"key":"e_1_3_3_23_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.43.5.1003"},{"key":"e_1_3_3_24_2","volume-title":"CLSI document M100-S17. 27","author":"Clinical and Laboratory Standards Institute","unstructured":"Clinical and Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing; 17th informational supplement. CLSI document M100-S17. 27. CLSI, Wayne, PA."}],"container-title":["Antimicrobial Agents and Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.02596-17","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.02596-17","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,21]],"date-time":"2022-02-21T16:23:52Z","timestamp":1645460632000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/AAC.02596-17"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,9]]},"references-count":23,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2018,9]]}},"alternative-id":["10.1128\/AAC.02596-17"],"URL":"https:\/\/doi.org\/10.1128\/aac.02596-17","relation":{},"ISSN":["0066-4804","1098-6596"],"issn-type":[{"value":"0066-4804","type":"print"},{"value":"1098-6596","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,9]]},"assertion":[{"value":"2017-12-21","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2018-07-05","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2018-08-27","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e02596-17"}}